Toronto Stock Exchange Symbol: DND

MISSISSAUGA, ON, June 4, 2012 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND; OTC: CPHMF), announced today that Larry Andrews, President and Chief Executive Officer, is presenting at the Bloom & Burton Healthcare Investor Conference, which is being held in Toronto on June 21 at the Toronto Board of Trade. Mr. Andrews will provide a corporate update and participate in a Q&A breakout session at 3:30 PM ET in room C/D.

Cipher's presentation will be available on their website www.cipherpharma.com.

About Cipher Pharmaceuticals Inc.

Cipher Pharmaceuticals (TSX: DND; OTC: CPHMF) is a growing specialty pharmaceutical company that commercializes novel formulations of successful, currently marketed molecules.  Cipher's strategy is to in-license clearly differentiated products, advance them through the clinical development and regulatory approval stages, and out-license to international marketing partners.  The Company's first product is a fenofibrate formulation marketed in the United States as Lipofen®. Cipher's second product, an extended-release tramadol, is marketed in the United States as ConZip™ and is marketed in Canada as Durela™.  Cipher's third product, a novel formulation of the acne treatment isotretinoin, was recently approved by the FDA and is expected to be launched in Q4 2012 as Absorica™.  The product is also currently being reviewed by Health Canada. For more information, please visit www.cipherpharma.com.